Boomerang Medical, a women-led innovator in bioelectronic medicine, has announced the closing of a $20 million Series B financing round co-led by Arboretum Ventures and Hatteras Venture Partners.
The funding will support the advancement of BOOM-IBD2, the first pivotal clinical trial evaluating implantable neuromodulation for inflammatory bowel disease (IBD), with an initial focus on ulcerative colitis. Patient enrollment is currently underway at leading medical centers across the United States under clinical trial identifier NCT06571669.
Ulcerative colitis, the most prevalent form of IBD, is a chronic autoimmune disorder affecting millions across North America and Europe. Despite its widespread impact, there are currently no device-based treatment options available.
Boomerang Medical is exploring sacral neuromodulation—a technique involving gentle electrical stimulation via a small implanted device—as a potential solution to reduce symptom burden and improve quality of life for patients. This approach builds on a strong safety record, with over 500,000 procedures performed globally in other therapeutic areas.
The BOOM-IBD2 trial design is informed by Boomerang’s earlier feasibility study involving 40 patients with Crohn’s disease and ulcerative colitis. That study provided critical insights into safety, tolerability, and early efficacy signals, laying the groundwork for this pivotal investigation. If successful, BOOM-IBD2 could pave the way for a new class of device-based therapies in autoimmune gastrointestinal conditions.
Boomerang Medical’s goal is to bring precision neuromodulation to underserved patient populations through rigorous science and thoughtful innovation. With this latest funding, the company is well-positioned to advance its clinical pipeline and potentially transform the treatment landscape for ulcerative colitis and beyond.
KEY QUOTES:
“Ulcerative colitis patients struggle with symptoms that profoundly affect their daily lives. Our pivotal trial asks a simple but critical question: can this therapy meaningfully reduce symptom burden and improve quality of life for people living with ulcerative colitis? With the continued support of our investors, we’re pursuing that answer for patients and their physicians.”
Heather Simonsen, CEO of Boomerang Medical
“There is a clear and significant unmet need for new approaches to help patients suffering from the debilitating symptoms of ulcerative colitis. We are impressed with the Boomerang team and their rigorous approach to clinical development. We are confident this financing will position them well to complete their pivotal trial and move this promising therapy forward.”
Tom Shehab, MD, gastroenterologist, Managing Partner at Arboretum Ventures and member of the Board of Directors
